Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

Expects Fiapta(TM) (Iloperidone) PDUFA Action July 27, 2008

Completes Enrollment for VEC-162 Phase III Chronic Insomnia Study

ROCKVILLE, Md., Feb. 14 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the fourth quarter and fiscal year ended December 31, 2007.

Vanda reported research and development (R&D) expenses in the fourth quarter of 2007 of $12.6 million, compared to third quarter of 2007 R&D expenses of $13.9 million and fourth quarter of 2006 R&D expenses of $7.9 million. The decrease in R&D expenses between the third and fourth quarters is primarily attributable to costs associated with the ongoing Phase III VEC-162 chronic insomnia clinical trial being offset by a non-recurring third quarter milestone charge of $5.0 million for the Fiapta(TM) New Drug Application (NDA) submission in September 2007. The increase in R&D expenses in the fourth quarter of 2007 relative to the fourth quarter of 2006 is primarily attributable to the same VEC-162 Phase III chronic insomnia clinical trial that was initiated in late 2007. For the full year of 2007, total R&D expenses were $47.2 million compared to $52.1 million during 2006. Total expenses for the fourth quarter of 2007 were $22.0 million, compared to $23.5 million in the third quarter of 2007 and $12.4 million in the fourth quarter of 2006. For the full year of 2007, total expenses were $80.0 million, compared to $65.7 million in 2006.

Net loss was $20.7 million for the fourth quarter of 2007, compared to $21.9 million in the third quar905) (378,739)

Changes in assets and liabilities:

Prepaid expenses and other

current assets 168,987 270,745

Deposits - 690,000

Accounts payable 204,029 526,711

Accrued expenses 3,465,028 3,811,373

Deferred grant revenue (147,464) -

Other liabilities 86,644 234,833

Net cash used in operating

activities (51,641,258) (51,619,518)

Cash flows from investing activities:

Purchases of property and equipment (279,433) (1,354,156)

Proceeds from sales of property

and equipment 200,179 -

Purchases of marketable securities (138,953,879) (102,232,608)

Proceeds from sales of marketable

securities 3,577,859 82,137,888

Maturities of marketable securities 86,695,000 29,670,000

Net cash provided by (used in)

investing activities (48,760,274) 8,221,124

Cash flows from financing activities:

Principal payments on obligations

under capital lease - (1,540)

Principal payments on note payable - (141,074)

Proceeds from exercise of stock options

and warrants 148,640 127,115

Proceeds from issuance of common stock,

net of issuance costs 111,254,850 53,329,951

Net cash provided by

financing activities 111,403,490 53,314,452

Effect of foreign currency translation (1,320) 22

Net increase in cash and cash equivalents 11,000,638 9,916,080

Cash and cash equivalents,

beginning of period 30,928,895 21,012,815

Cash and cash equivalents, end of period $41,929,533 $30,928,895

ter of 2007 and $11.9 million in the fourth quarter of 2006. Net loss per common share for the fourth quarter of 2007 was $0.78, compared to $0.82 in the third quarter of 2007, and $0.54 in the fourth quarter of 2006.

As of December 31, 2007, Vanda's cash, cash equivalents, and marketable securities totaled approximately $93.2 million. As of December 31, 2007, the company had a total of approximately 26.6 million shares of common stock outstanding.

"I am extremely pleased with the successful submission and acceptance of the Fiapta(TM) NDA filing in 2007. This important achievement would not have been possible without the commitment and dedication of the Vanda team," stated Mihael Polymeropoulos, M.D., President and CEO of Vanda. "I am looking forward to an exciting 2008 during which we expect the results from our VEC-162 Phase III chronic insomnia clinical trial and the PDUFA action for Fiapta(TM)."

OPERATIONAL HIGHLIGHTS

Iloperidone

On September 27, 2007 Vanda announced that it had submitted an NDA to the U.S. Food and Drug Administration (FDA) for Fiapta(TM), its investigational atypical antipsychotic for the treatment of schizophrenia. On November 27, 2007 the company announced that the FDA had accepted and filed the NDA. Under the Prescription Drug User Fee Act (PDUFA) of 1992, Vanda expects a PDUFA action on or about July 27, 2008.

VEC-162

Vanda has completed enrollment for its VEC-162 Phase III chronic insomnia clinical trial. Vanda expects to report top-line results in June 2008. Vanda enrolled 324 patients in the trial, which is a randomized, double-blind, placebo-controlled 35-day study, measuring sleep onset and maintenance, as well as next-day performance.

FINANCIAL DETAILS

-- Operating Expenses. Fourth quarter 2007 R&D expenses, primarily

consisting of salaries and related costs of R&D personnel, stock-based

compensation, and the costs of consultants, materials and supplies

associated with the company's clinical trials and research initiatives,

were $12.6 million, down from $13.9 million in the previous quarter and

up from $7.9 million in the fourth quarter of 2006. The decrease in R&D

expenses between the third and fourth quarters of 2007 is primarily

attributable to an increase in VEC-162 Phase III chronic insomnia

clinical trial costs being offset by a non-recurring third quarter

milestone charge of $5.0 million for the Fiapta(TM) NDA submission in

September 2007. The increase in R&D expenses in the fourth quarter of

2007 relative to the fourth quarter of 2006 is primarily attributable

to the same VEC-162 Phase III chronic insomnia clinical trial that was

initiated in late 2007. For the full year of 2007, total R&D expenses

were $47.2 million, down from $52.1 million in the full year of 2006.

Lower R&D expenses in 2007 resulted from the substantial completion of

the Fiapta(TM) Phase III clinical program in 2006.

General and administrative (G&A) expenses totaled $9.5 million in the

fourth quarter of 2007, down slightly from $9.6 million in the third

quarter of 2007, and up from $4.5 million in the fourth quarter of

2006. The increase in G&A expenses in the fourth quarter of 2007

relative to the fourth quarter of 2006 is primarily due to increased

Fiapta(TM) pre-launch commercial activities, stock-based compensation

charges, salaries and related costs of non-R&D personnel, insurance and

facility expenses. For the full year of 2007, total G&A expenses were

$32.8 million, up from $13.6 million in the prior year. The increase

in G&A expenses is primarily due to increased salaries, benefits and

stock-based compensation expense, increased business and commercial

development expenses, and higher insurance, legal and professional fees

associated with being a public company.

Employee stock-based compensation expense recorded in the fourth

quarter of 2007 was $5.2 million. Of the total $5.2 million of

non-cash charges, $1.0 million was recorded in R&D expenses and

$4.2 million was recorded in G&A expenses. In the third quarter of

2007 and the fourth quarter of 2006, total stock-based compensation was

$5.2 million and $1.6 million, respectively. For the full year of

2007, total stock-based compensation was $19.5 million, up from

$6.1 million in the prior year. The increase in stock-based

compensation is primarily the result of the higher fair value of

options granted during 2007 compared to options granted in prior

periods.

-- Net loss for the fourth quarter of 2007 was $20.7 million. This

compares to a net loss of $21.9 million in the third quarter of 2007,

and $11.9 million in the fourth quarter of 2006. For the full year of

2007, net loss was $74.1 million, up from $63.5 million for the full

year of 2006.

-- Net loss per common share for the fourth quarter of 2007 was $0.78,

compared to $0.82 in the third quarter of 2007 and $0.54 in the fourth

quarter of 2006. For the full year of 2007, net loss per common share

was $2.81, compared to $3.97 in the full year of 2006.

-- Cash and marketable securities decreased by $16.2 million during the

fourth quarter. Changes included $20.7 million of net losses and

decreases in accrued R&D expenses and accounts payable of $2.5 million,

offset by $5.3 million in non-cash depreciation, amortization, and

stock-based compensation expenses, decreases in prepaid expenses of

$1.6 million and net decreases in other working capital of

$0.1 million.

-- Vanda's cash, cash equivalents, and marketable securities at the end of

the fourth quarter of 2007 totaled approximately $93.2 million,

compared to approximately $109.4 million as of September 30, 2007, and

approximately $31.9 million as of December 31, 2006.

FINANCIAL GUIDANCE

The company anticipates that its current cash balance will be sufficient to fund operations through the Fiapta(TM) PDUFA action date and into the fourth quarter of 2008. Vanda plans to focus its efforts primarily on completing and reporting the top-line results for the ongoing VEC-162 Phase III chronic insomnia clinical trial and continuing essential Fiapta(TM) pre-launch commercial activities.

CONFERENCE CALL

The company has scheduled a conference call for today, Thursday, February 14, 2008 at 10:30 AM ET. During the call, Mihael H. Polymeropoulos, M.D., President and CEO, and Steven A. Shallcross, Sr. Vice President and CFO, will discuss quarterly results and other corporate activities. Investors can call 1-866-578-5747 (domestic) and 1-617-213-8054 (international) prior to the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. A replay of the call will be available Thursday, February 14, 2008, at 12:30 PM ET and will be accessible until Thursday, February 21, 2008, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 16341258.

The conference call will be broadcast simultaneously on the company's Web site, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, and install any necessary software. The call will also be archived on the Vanda Web site for a period of 30 days, through March 15, 2008.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, Fiapta(TM) (iloperidone), is a compound for the treatment of schizophrenia and bipolar disorder, for which Vanda has recently submitted an NDA to the FDA. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended September 30, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

Three Months Ended Year Ended

December 31, December 31, December 31, December 31,

2007 2006 2007 2006

Revenues from

services $ - $ - $ - $ -

Operating expenses:

Research and

development 12,574,735 7,939,988 47,234,867 52,070,776

General and

administrative 9,472,938 4,467,225 32,803,508 13,637,664

Total

operating

expenses 22,047,673 12,407,213 80,038,375 65,708,440

Loss from

operations (22,047,673) (12,407,213) (80,038,375) (65,708,440)

Interest income 1,299,076 516,291 5,907,219 2,202,654

Interest expense - (4) - (4,833)

Other income - - 71,345 -

Total other

income, net 1,299,076 516,287 5,978,564 2,197,821

Loss before tax

provision (20,748,597) (11,890,926) (74,059,811) (63,510,619)

Income tax

provision (191) 549 9,879 549

Net loss $ (20,748,406) $ (11,891,475) $ (74,069,690) $ (63,511,168)

Basic and

diluted net

loss per

common share $ (0.78) $ (0.54) $ (2.81) $ (3.97)

Shares used in

calculation of

basic and

diluted

net loss

per common

share 26,644,540 21,932,730 26,360,177 16,001,815

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

December 31, 2007 December 31, 2006

ASSETS

Current assets:

Cash and cash equivalents $41,929,533 $30,928,895

Marketable securities 43,243,960 941,981

Prepaid expenses, deposits and

other current assets 1,781,881 1,949,466

Total current assets 86,955,374 33,820,342

Marketable securities, long-term 7,979,331 -

Property and equipment, net 1,345,845 1,859,704

Deposits 150,000 150,000

Restricted cash 430,230 430,230

Total assets $96,860,780 $36,260,276

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $2,988,069 $2,783,249

Accrued expenses 9,789,738 6,322,808

Total current liabilities 12,777,807 9,106,057

Long-term liabilities:

Deferred rent 354,042 238,413

Deferred grant revenue - 129,950

Other long-term liabilities - 28,984

Total liabilities 13,131,849 9,503,404

Stockholders' equity:

Common stock 26,653 22,129

Additional paid-in capital 257,600,368 126,578,588

Accumulated other comprehensive

gain (loss) 12,176 (3,269)

Deficit accumulated during the

development stage (173,910,266) (99,840,576)

Total stockholders' equity 83,728,931 26,756,872

Total liabilities and

stockholders' equity $96,860,780 $36,260,276

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Year Ended

December 31, December 31,

2007 2006

Cash flows from operating activities:

Net loss $(74,069,690) $(63,511,168)

Adjustments to reconcile net income

to net cash used in operating

activities:

Depreciation and amortization 571,586 575,372

Employee and non-employee

stock-based compensation 19,622,814 6,131,827

Loss on disposal of assets 28,713 29,528

Accretion of discount on investments (1,571,
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):